Category: Pα+ - Page 2 - Psychedelic Alpha

Part 2 of our Year in Review video series is out now.

Read more about the article Pα+ Psychedelic Bulletin #214: LSD Microdosing Program Collapses; AtaiBeckley’s Phase 2b Debrief; UK Government Responds to MPs’ Psilocybin-Related Questions

Pα+ Psychedelic Bulletin #214: LSD Microdosing Program Collapses; AtaiBeckley’s Phase 2b Debrief; UK Government Responds to MPs’ Psilocybin-Related Questions

Post published:November 19, 2025
Post category:Psychedelic Bulletin Pα+

Read more about the article AtaiBeckley Posts Positive Phase 2b Open-Label Extension Data for 5-MeO-DMT, Plots Phase 3

AtaiBeckley Posts Positive Phase 2b Open-Label Extension Data for 5-MeO-DMT, Plots Phase 3

Post published:November 10, 2025
Post category:Analysis News Pα+

Read more about the article Pα+ Psychedelic Bulletin #213: Compass Accelerates Psilocybin Launch Planning; Australian VA Funds Psychedelic Therapy for Veterans; AbbVie Paid $900M Upfront for Psychedelic Candidate

Pα+ Psychedelic Bulletin #213: Compass Accelerates Psilocybin Launch Planning; Australian VA Funds Psychedelic Therapy for Veterans; AbbVie Paid $900M Upfront for Psychedelic Candidate

Post published:November 7, 2025
Post category:Psychedelic Bulletin Pα+

Read more about the article Compass Pathways Accelerates Psilocybin Launch Timeline by 9-12 Months

Compass Pathways Accelerates Psilocybin Launch Timeline by 9-12 Months

Post published:November 4, 2025
Post category:Analysis News Pα+

Read more about the article Pα+ Psychedelic Bulletin #212: Delix Posts Early Efficacy Signal; NRx Wants FDA to Ban Competitors’ Ketamine; Cybin Raises $175M

Pα+ Psychedelic Bulletin #212: Delix Posts Early Efficacy Signal; NRx Wants FDA to Ban Competitors’ Ketamine; Cybin Raises $175M

Post published:October 31, 2025
Post category:Psychedelic Bulletin Pα+

Read more about the article Q3’25 Psychedelic Lobbying Update

Q3’25 Psychedelic Lobbying Update

Post published:October 29, 2025
Post category:Analysis News Pα+

Read more about the article Pα+ Psychedelic Bulletin #211: AbbVie Officially Enters Psychedelics; atai-Beckley’s 5-MeO-DMT Scores Breakthrough Therapy Designation; California Bill Signed

Pα+ Psychedelic Bulletin #211: AbbVie Officially Enters Psychedelics; atai-Beckley’s 5-MeO-DMT Scores Breakthrough Therapy Designation; California Bill Signed

Post published:October 24, 2025
Post category:Psychedelic Bulletin Pα+

Read more about the article Q3’25 Investor Survey: What are Investors Most Concerned About?

Q3’25 Investor Survey: What are Investors Most Concerned About?

Post published:October 23, 2025
Post category:Analysis News Pα+

Read more about the article Q3’25 Survey: What are Psychedelics Investors Excited About?

Q3’25 Survey: What are Psychedelics Investors Excited About?

Post published:October 21, 2025
Post category:Analysis News Pα+

Read more about the article September 2025 Psychedelic Patent Update

September 2025 Psychedelic Patent Update

Post published:October 20, 2025
Post category:Psychedelic Patent Analysis Pα+

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.